RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE

NCT02142959 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

187

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Omaveloxolone Lotion 0.5%
DRUG: Omaveloxolone Lotion 3%
DRUG: Vehicle Lotion
RADIATION: 3D conformal radiation therapy

Sponsor

Biogen

Collaborators

[object Object]